Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.

•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity.•Immunotherapy may have the potential for durable remissions in ovarian cancer.